GuShiio.com ① Huawei’s Data Storage Public Account released information stating that it will release a Ruijin pathology model based on Huawei’s DCS AI solution.
② Jianghai Securities pointed out that under the guidance of the “Healthy China 2030” strategy, the medical industry is ushering in important opportunities for intelligent upgrading.
Huawei’s Data Storage Public Account released information stating that it will release a Ruijin pathology model based on Huawei’s DCS AI solution. According to reports, the model will be released at the “2025 Medical Artificial Intelligence and Precision Diagnosis and Treatment Development Forum” held on February 18.
Pathological diagnosis is a diagnosis method based on image information and is known as the “gold standard” for disease diagnosis. At present, the development of my country’s pathology industry is faced with the characteristics of lack of pathologists, uneven distribution, and long culture cycles. “Automation, standardization, digitalization, and intelligence” have become an inevitable trend in the development of pathology. Jianghai Securities pointed out that the breakthrough development of AI is promoting the leap of medical diagnosis and treatment from traditional empirical medicine to data-driven precision medicine. Under the guidance of the “Healthy China 2030” strategy, the medical industry is ushering in important opportunities for intelligent upgrades.
According to the Cailian theme library, among the relevant listed companies:
Daan geneSaid that in terms of AI-assisted diagnosis applications, the joint-stock company Yunkang Group has successfully introduced AI-assisted diagnosis of pathological DNA polyploidy, AI-assisted diagnosis of cervical liquid-based cells, and AI analysis of chromosomes, and the diagnosis efficiency has been greatly improved.
Dean diagnosticsSaid that in 2024, the company’s subsidiary Medical Policy Technology will assist the provincial-level digital pathology service system in Hubei Province, and has signed contracts with more than 70 local hospitals, with a local pathology AI market share of approximately 70%. Dean’s own laboratory has provided more than 3 million AI pathology diagnosis reports using related products.
Related stocksDaan gene+10.07%Dean diagnostics+18.95%
